Starting November 1, 2026, the UAE will implement a total ban on the use of ciprofloxacin in veterinary medicine. This move, spearheaded by the Emirates Drug Establishment (EDE), aims to curb the growing threat of antimicrobial resistance. Because ciprofloxacin belongs to the fluoroquinolone class—medications classified as "Critically Important Antimicrobials" for humans—authorities are concerned that its use in animals could lead to resistant bacteria that render essential human treatments ineffective.

The regulation mandates that nine specific veterinary products, including both imports and locally produced items, be removed from the market. Companies are now required to halt production and supply, with instructions to either re-export or properly dispose of existing stocks before the deadline. To ensure total compliance, the EDE is rolling out a strict monitoring plan and has already begun notifying industry stakeholders of their responsibilities. Dr. Ruqaya Aqeel Al Bastaki emphasized that this decision is backed by scientific research, including studies from UAE University, reflecting a proactive approach to prioritizing public health and maintaining the efficacy of critical human medicines.